A nutrient selected from the group consisting of beta-carotene, fiber, Vitamin C, Folate, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12 and Potassium, or combination of two of more thereof, for use in treating or preventing mastitis, especially subclinical mastitis, in a subject.

The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that provides a dose of merotocin greater than 100 μg or substantially about 400 μg to the female. The disclosure encompasses methods of treatment as well as compositions for use in such methods.

The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that provides a dose of merotocin greater than 100 μg or substantially about 400 μg to the female. The disclosure encompasses methods of treatment as well as compositions for use in such methods.

The present invention relates to pharmaceutical compositions having improved stability.

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.

The application relates to a compound having Formula (I):

##STR00001##

which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a centration of 2-30 g/L and vitamin C having a concentration of 1-14.3 g/L. The antioxidant complex provided in the present invention can effectively reduce the number of somatic cells in a diary cow and improve milk quality.

Disclosed are uses of a Pulsatilla saponin compound B4 or a pharmaceutically acceptable salt thereof in preparing a drug for treating viral and/or bacterial diseases. The Pulsatilla saponin compound B4 disclosed by the invention shows a strong biological activity, and efficiently treats endometritis, footrot, feline parvovirus, canine parvovirus, canine distemper, canine kidney failure, and canine acute nephritis. ##STR00001##

The present invention provides stapled polypeptides of the Formulae (I) and (VI):

##STR00001##

and salts thereof; wherein the groups ; R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2a, R.sup.3a, R.sup.2b, R.sup.3b, R.sup.4a, R.sup.4b, R.sub.A, R.sub.Z, L.sub.1a, L.sub.1b, L.sub.2, L.sub.3, X.sup.AA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.